Image

Global Hepatic Antiviral Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Hepatic Antiviral Drugs Market, By Application (Hepatitis A, Hepatitis B, Hepatitis C, Others), Drugs (Entecavir, Tenofovir, lamivudine, Adefovir, Telbivudine, Others), Dosage (Powder, Tablet, Solution, Liquid, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

 

Hepatic Antiviral Drugs Market

Market Analysis and Size

In recent years, the hepatic antiviral drugs market is anticipated to grow rapidly during the forecast period. According to the 2019 study "Burden of Liver Diseases in the World," liver illness causes roughly 2 million fatalities per year worldwide, with 1 million deaths owing to cirrhosis complications and 1 million deaths due to viral hepatitis and hepatocellular cancer. Cirrhosis is the 11th most prevalent cause of mortality globally, while liver cancer is the 16th most common cause of death. In addition, chronic liver disease mortality in the United States is predicted to climb, owing to an increase in non-alcoholic fatty liver disease (NAFLD). The increased prevalence of liver illnesses aided in the market's expansion.

Data Bridge Market Research analyses that the hepatic antiviral drugs market was valued at USD 16.11 billion in 2021 and is expected to reach USD 23.05 billion by 2029, registering a CAGR of 4.58% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Antiviral drugs are a type of medicine that is used to treat viral illnesses like HIV, herpes, hepatitis, and influenza. Vaccines are the most common form of administration for these medications. Furthermore, the majority of these medications are used to treat specific viral infections, but a select handful (broad-spectrum antiviral treatments) are effective against different virus forms. Antiviral medications used to treat viral infections of the liver, such as hepatitis, are known as hepatic antiviral agents.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Application (Hepatitis A, Hepatitis B, Hepatitis C, Others), Drugs (Entecavir, Tenofovir, lamivudine, Adefovir, Telbivudine, Others), Dosage (Powder, Tablet, Solution, Liquid, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), AstraZeneca (UK), AbbVie Inc. (US), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Sun Pharmaceutical Industries Ltd. (Mumbai),  Apotex Inc. (Canada), Amneal Pharmaceuticals LLC. (US), Bristol-Myers Squibb Company (US), Zydus Cadila (Ahmedabad), Gilead Sciences, Inc. (US)

Market Opportunities

 

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Hepatic Antiviral Drugs Market Dynamics

Drivers

  • Increasing prevalence of hepatic disease

The rising prevalence of hepatic disease is a primary driver of the hepatic antiviral drugs market's growth. Changing dietary pattern and sedentary lifestyle are the factors that will enhance the prevalence of urticaria and influencing the market dynamics during the forecast period.  

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of hepatic antiviral drugs market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hepatic antiviral drugs market. Additionally, high disposable income and increasing awareness about the treatment will result in the expansion of hepatic antiviral drugs market. Along with this, rising geriatric population and rising incidences of auto-immune disorders will enhance the growth rate of the market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hepatic antiviral drugs market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the hepatic antiviral drugs market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment of hepatic antiviral drugs will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hepatic antiviral drugs market. Additionally, strict regulations and the dearth of awareness about treatment for this illness will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This hepatic antiviral drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hepatic antiviral drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Hepatic antiviral drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Hepatic Antiviral Drugs Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency.

COVID-19 has been linked to liver illness in an increasing number of patients. Multiple mechanisms can contribute to COVID19 liver injury, including virus-induced systemic inflammation, hypoxia, hepatic congestion, and drug-induced liver disease. COVID19 has been linked to hepatic decompensation and liver-related death in cirrhotic patients. COVID19's influence on healthcare resources has had a negative impact on chronic liver disease patient treatment and results. As a result, the treatment, diagnosis, and follow-up of individuals with liver disease has decreased, resulting in negative effects for the healthcare industry as a whole. Hence, COVID-19 pandemic had a severe impact on the growth of hepatic antiviral drugs market.

Recent Development

  • In December 2021, Pfizer had received the emergency use authorization from U.S. Food and (FDA) for Novel COVID-19 oral antiviral drug named PAXLOVID. PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) is approved for emergency use in high-risk adults and children 12 years and older who weigh at least 40 kg.
  • In December 2021, Cipla Limited had received the Emergency Use Authorization (EUA) permission by Drug Controller General of India (DCGI) for the launch of oral anti-viral COVID drug named Molnupiravir. Molnupiravir is the first oral antiviral to be authorized by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 infection in people who are at high risk of developing severe disease.

Global Hepatic Antiviral Drugs Market Scope

The hepatic antiviral drugs market is segmented on the basis of application, drugs, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Others

On the basis of application, the global hepatic drugs market is segmented into hepatitis A, hepatitis B, hepatitis C and others.

Drugs

  • Entecavir
  • Tenofovir
  • Lamivudine
  • Adefovir
  • Telbivudine
  • Others

On the basis of drugs, the global hepatic antiviral drugs market is segmented into entecavir, tenofovir, lamivudine, adefovir, telbivudine and others.

Dosage

  • Powder
  • Tablet
  • Solution
  • Liquid
  • Others

On the basis of dosage, the hepatic antiviral drugs market is segmented into powder, tablet, solution, liquid, and others.  

Route of Administration

  • Oral
  • Parenteral
  • Others

The route of administration segment for the hepatic antiviral drugs market is segmented into oral, parenteral and others.

 End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

On the basis of end-users, the hepatic antiviral drugs market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the hepatic antiviral drugs market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Hepatic Antiviral Drugs Market Regional Analysis/Insights

The Hepatic antiviral drugs market is analysed and market size insights and trends are provided by country, application, drugs, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Hepatic antiviral drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America and Europe dominate the hepatic antiviral drugs market because of the growing prevalence of auto-immune diseases in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to number of population and rising prevalence of hepatic diseases in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Hepatic Antiviral Drugs Market Share Analysis

The Hepatic antiviral drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hepatic antiviral drugs market.

Some of the major players operating in the hepatic antiviral drugs market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Jerusalem)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Eli Lilly and Company (US)
  • Merck & Co., Inc. (US)
  • Allergan (Ireland)
  • AstraZeneca (UK)
  • AbbVie Inc. (US)
  • Aurobindo Pharma (Hyderabad)
  • Lupin (Mumbai)
  • Sun Pharmaceutical Industries Ltd. (Mumbai)
  • Apotex Inc. (Canada)
  • Amneal Pharmaceuticals LLC. (US)
  • Bristol-Myers Squibb Company (US)
  • Zydus Cadila (Ahmedabad)
  • Gilead Sciences, Inc. (US)
  • Johnson & Johnson Private Limited (US)
  • Cipla Inc. (US)  

Research Methodology: Global Hepatic Antiviral Drugs Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The market value for Hepatic Antiviral Drugs Market is expected USD 23.05 billion by 2029.
The Hepatic Antiviral Drugs Market is to grow at a CAGR of 4.58% during the forecast by 2029
The expansion of the Global Hepatic Antiviral Drugs Market will be fueled by the changing dietary pattern as well as sedentary lifestyle and rising prevalence of urticaria. Additionally, increasing expenditure on healthcare infrastructure and increasing geriatric population will enhance the growth rate of global hepatic antiviral drugs market.
The major players operating in the Hepatic Antiviral Drugs Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), AstraZeneca (UK), AbbVie Inc. (US), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Sun Pharmaceutical Industries Ltd. (Mumbai), Apotex Inc. (Canada), Amneal Pharmaceuticals LLC. (US), Bristol-Myers Squibb Company (US), Zydus Cadila (Ahmedabad), Gilead Sciences, Inc. (US).